fatty acid oxidation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-21 and is reviewed periodically as new material appears.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Industrial BioTest Labs (IBT) was the most notable whistleblower case where thousands of safety tests for chemical manufacturers were either falsely claimed to have been performed or were of such poor quality that police investigators could not determine the extent of the work completed, despite superficially delivering test results as specified in their contracts with the manufacturers. IBT, a contract laboratory based in Northbrook, Illinois, conducted research for the United States government and various chemical and pharmaceutical companies, both from the U.S. and abroad, and submitted toxicology data to several federal agencies, covering a wide range of products including drugs, insecticides, herbicides, food additives, pesticides, cosmetics, and cleaning products. These issues were aired in hearings at the US Congress, which pressured the FDA to propose draft Regulations on GLP on November 19, 1976, and establishment of the Final Rule in June 1979 which became effective on June 20, 1979. Proposed amendments were introduced on October 29, 1984. The GLP amendment Final Rule was published on September 4, 1987 and became effective on October 5, 1987. Many of the fraudulent safety data concerned chemicals overseen by the new Environmental Protection Agency (EPA), so their GLP rule was developed simultaneously with FDA, the EPA issuing its draft GLP regulations in 1979 and 1980, publishing the Final Rules in two separate parts (40 CFR 160 and 40 CFR 792) in 1983.
Other appropriate antihypertensive drugs to administer during hypertensive crisis resulting from stimulant overdose are vasodilators such as nitroglycerin, diuretics such as furosemide, and alpha blockers such as phentolamine. Beta blockers were found to be associated with depression in earlier studies. More lipophilic beta blockers, with greater central effects, were especially implicated. However, subsequent more rigorous studies found no causal relationship of beta blockers with depression and regardless of lipid solubility. A small and significant but inconsistent risk of fatigue was found for non-selective beta blockers however. Beta blockers, due to their antagonism at β1 adrenergic receptors, inhibit both the synthesis of new melatonin and its secretion by the pineal gland. More lipophilic beta blockers, with greater ability to cross the blood–brain barrier, are known to be able to suppress melatonin release by 50 to 80%. The neuropsychiatric side effects of some beta blockers (e.g. sleep disruption, insomnia) may be related to this effect.
Hydroxynorketamine (HNK), or 6-hydroxynorketamine, is a minor metabolite of the anesthetic, dissociative, and antidepressant drug ketamine. It is formed by hydroxylation of the intermediate norketamine, another metabolite of ketamine. As of late 2019, (2R,6R)-HNK is in clinical trials for the treatment of depression. The major metabolite of ketamine is norketamine (80%). Norketamine is secondarily converted into 4-, 5-, and 6-hydroxynorketamines (15%), mainly HNK (6-hydroxynorketamine). Ketamine is also transformed into hydroxyketamine (5%). As such, bioactivated HNK comprises less than 15% of a dose of ketamine.
His work on isotopes also led to his formulation of the whole number rule which states that "the mass of the oxygen isotope being defined [as 16], all the other isotopes have masses that are very nearly whole numbers", a rule that was used extensively in the development of nuclear energy. The exact mass of many isotopes was measured leading to the result that hydrogen has a 1% higher mass than expected by the average mass of the other elements. Aston speculated about the subatomic energy and the use of it in 1936. Isotopes and Mass-spectra and Isotopes are his most well-known books.
Sources: en.wikipedia.org
A potential application for MOFs is biological imaging and sensing via photoluminescence. A large subset of luminescent MOFs use lanthanides in the metal clusters. Lanthanide photoluminescence has many unique properties that make them ideal for imaging applications, such as characteristically sharp and generally non-overlapping emission bands in the visible and near-infrared (NIR) regions of the spectrum, resistance to photobleaching or "blinking", and long luminescence lifetimes. However, lanthanide emissions are difficult to sensitize directly because they must undergo LaPorte forbidden f-f transitions. Indirect sensitization of lanthanide emission can be accomplished by employing the "antenna effect", where the organic linkers act as antennae and absorb the excitation energy, transfer the energy to the excited state of the lanthanide, and yield lanthanide luminescence upon relaxation. A prime example of the antenna effect is demonstrated by MOF-76, which combines trivalent lanthanide ions and 1,3,5-benzenetricarboxylate (btc) linkers to form infinite rod SBUs coordinated into a three dimensional lattice. As demonstrated by multiple research groups, the BTC linker can effectively sensitize the lanthanide emission, resulting in a MOF with variable emission wavelengths depending on the lanthanide identity. Additionally, the Yan group has shown that Eu3+- and Tb3+- MOF-76 can be used for selective detection of acetophenone from other volatile monoaromatic hydrocarbons. Upon acetophenone uptake, the MOF shows a sharp decrease, or quenching, of the luminescence intensity.
In 1876, the former GOCA Freemason and high-ranking member in the Provincial Mother Lodge member Aurelio Almeida y González went on a tour of the United States. Here, he obtained broad support from the Masonic bodies of North America. In July 1876, back in Cuba, the Mother Lodge started asking questions about the money that the Supreme Council had been asking the Lodges to pay, and insisted on a proper accounting – but their effort was suppressed. Later in July, Almeida y González sent a telegraph cable to the Mother Lodge. On July 28, 1876, days after Almeida y González's telegraph arrived in Cuba, the Mother Lodge dissolved itself. On August 1, 1876, representatives from thirteen Cuban lodges (9 chartered lodges and 4 under dispensation) met in Havana to form the Gran Logia de la Isla de Cuba (English: Grand Lodge of the Island of Cuba). Under the charter of the Grand Lodge of Island of Cuba, the Higher Degrees were overseen in Cuba by the Grand Orient of Spain and Práxedes Mateo Sagasta. Within a month, the Grand Lodge of Cuba possessed 17 lodges. The new "Cuban" Freemasonry was effectively a restructuring and reorganization of GOCA Freemasonry and its Lodges, but the Grand Lodge of Cuba was now considered "regular and correct," officially abandoning GOCA's ideology of direct political action. This allowed them to obtain recognition from the majority of Grand Lodges in North America. In mainland Spain, the Spanish Restoration was underway, and the Cuban government was starting to introduce new legislation and freedoms with the aim to end the Ten Years' War.
By the end of the 20th century in North America, few new doctors went directly from medical school into independent, unsupervised medical practice, and more state and provincial governments began requiring one or more years of postgraduate training for medical licensure. Residencies are traditionally hospital-based, and in the middle of the 20th century, residents would often live (or "reside") in hospital-supplied housing. "Call" (night duty in the hospital) was sometimes as frequent as every second or third night for up to three years. Pay was minimal beyond room, board, and laundry services. It was assumed that most young men and women training as physicians had few obligations outside of medical training at that stage of their careers. The first year of practical patient-care-oriented training after medical school has long been termed "internship". Even as late as the middle of the twentieth century, most physicians went into primary care practice after a year of internship. Residencies were separate from internship, often served at different hospitals, and only a minority of physicians did residencies. In the United States, the Libby Zion case, which led to the Libby Zion Law, garnered attention in 1984, shed light on the demanding work hours imposed on medical residents. Responding to this concern, the Association of American Medical Colleges released a position statement in 1988, recommending a cap of 80 work hours per week for residents.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.